carcinoma (Cancer)
Information
- Disease name
- carcinoma
- Disease ID
- DOID:305
- Description
- "A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells." [url:http\://en.wikipedia.org/wiki/Carcinoma]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| AR | X | 67,544,021 | 67,730,619 | 4 |
| KIT | 4 | 54,657,913 | 54,740,770 | 2 |
| CHEK2 | 22 | 28,687,763 | 28,741,838 | 2 |
| TSC2 | 16 | 2,047,985 | 2,089,491 | 2 |
| TP53 | 17 | 7,668,421 | 7,687,490 | 2 |
| IGF2R | 6 | 159,969,082 | 160,111,504 | 2 |
| PTPN11 | 12 | 112,419,112 | 112,504,764 | 2 |
| PTCH1 | 9 | 95,442,980 | 95,509,266 | 2 |
| FGFR4 | 5 | 177,086,915 | 177,098,144 | 2 |
| PTCH2 | 1 | 44,821,938 | 44,843,253 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04222972 | Active, not recruiting | Phase 3 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | July 24, 2020 | June 30, 2025 |
| NCT03952403 | Active, not recruiting | Phase 3 | A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | December 2, 2019 | March 15, 2024 |
| NCT04362072 | Active, not recruiting | Phase 4 | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer | September 29, 2020 | June 25, 2024 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT03857620 | Active, not recruiting | N/A | Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer | July 24, 2019 | October 2025 |
| NCT03515174 | Active, not recruiting | N/A | Trial Comparing Active Intervention At Diagnosis With Usual Care to Improve Psycho-social Care in AYAO | April 16, 2018 | April 2024 |
| NCT03208374 | Active, not recruiting | Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling | June 27, 2017 | June 2026 | |
| NCT04600206 | Active, not recruiting | Existential Distress in Patients With Advanced Cancer and Their Caregivers | October 23, 2020 | June 2024 | |
| NCT03091192 | Active, not recruiting | Phase 3 | Savolitinib vs. Sunitinib in MET-driven PRCC. | July 25, 2017 | December 31, 2024 |
| NCT05241873 | Active, not recruiting | Phase 1/Phase 2 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | March 4, 2022 | July 25, 2026 |
| NCT01061515 | Active, not recruiting | Phase 1 | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | May 10, 2011 | September 27, 2024 |
| NCT04641819 | Active, not recruiting | Phase 4 | Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients | April 27, 2021 | June 30, 2024 |
| NCT04862780 | Active, not recruiting | Phase 1/Phase 2 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | June 29, 2021 | January 31, 2025 |
| NCT00327652 | Completed | Phase 1 | Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases | October 2006 | |
| NCT00364455 | Completed | Phase 3 | Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer. | December 2002 | March 2006 |
| NCT00420381 | Completed | Phase 2 | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer | January 2007 | December 2014 |
| NCT00446446 | Completed | Phase 2 | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | October 30, 2007 | November 29, 2017 |
| NCT00447005 | Completed | Phase 1 | Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors | February 2007 | August 2009 |
| NCT00466583 | Completed | Phase 1 | Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma | March 2007 | June 2011 |
| NCT00506051 | Completed | Phase 1 | ZD6474(Vandetanib) + Alimta Combo Study | July 2005 | October 2011 |
| NCT00518349 | Completed | N/A | Colonoscope Passive Bending Function | August 2003 | December 2009 |
| NCT00532155 | Completed | Phase 3 | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | September 2007 | October 2011 |
| NCT00565448 | Completed | Phase 2 | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents | November 2007 | January 2012 |
| NCT00599755 | Completed | Phase 1 | Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3) | January 1, 2009 | April 13, 2011 |
| NCT00613652 | Completed | Phase 1 | A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients | January 2008 | June 2009 |
| NCT00613691 | Completed | Phase 1 | A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma | January 2008 | December 2012 |
| NCT00688623 | Completed | Phase 2 | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe | June 24, 2009 | November 7, 2016 |
| NCT00688753 | Completed | Phase 2 | RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe | July 2009 | October 2014 |
| NCT00719264 | Completed | Phase 2 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | November 12, 2008 | April 15, 2013 |
| NCT00728130 | Completed | Phase 1 | Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients | May 2008 | June 2010 |
| NCT00731861 | Completed | Phase 1 | Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors | May 2005 | August 2010 |
| NCT00737243 | Completed | Phase 2 | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site | August 2008 | December 2012 |
| NCT00742222 | Completed | Phase 4 | Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer | May 2008 | January 2015 |
| NCT00752570 | Completed | Phase 2 | A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma | November 2008 | June 2012 |
| NCT00770536 | Completed | Phase 1 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | January 2009 | June 2015 |
| NCT00781911 | Completed | Phase 2 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | February 2009 | May 2016 |
| NCT00799084 | Completed | Phase 2 | Automated Telephone Monitoring for Symptom Management | April 2003 | November 2006 |
| NCT00816764 | Completed | Phase 1 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer | October 2008 | June 2010 |
| NCT00822809 | Completed | Phase 3 | CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers | December 2008 | April 2011 |
| NCT00838201 | Completed | Phase 3 | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | February 1, 2009 | May 3, 2012 |
| NCT00847912 | Completed | Phase 4 | CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial | June 26, 2009 | July 30, 2016 |
| NCT00863746 | Completed | Phase 3 | A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). | April 2009 | April 2013 |
| NCT00879554 | Completed | Phase 1 | A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors | February 2007 | November 2010 |
| NCT00879684 | Completed | Phase 1 | Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors | January 2008 | April 2011 |
| NCT00941863 | Completed | Phase 1 | Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006) | July 2002 | April 2008 |
| NCT00952874 | Completed | Molecular Biology of Anal Cancer in HIV-Positive Patients | July 2009 | June 2010 | |
| NCT01035229 | Completed | Phase 3 | Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | April 2010 | October 2013 |
| NCT01043523 | Completed | Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions. | December 2009 | April 2013 | |
| NCT01061645 | Completed | Phase 1 | Study of MOC31-PE in Antigen Positive Carcinomas | September 2010 | February 2012 |
| NCT01070537 | Completed | Phase 2 | Evaluation of the Bonfils Fiberscope for Predicted Difficult Intubation in Awake Patients With Ear, Nose, and Throat (ENT) Cancer (INVIBO) | February 2008 | April 2009 |
| NCT00001569 | Completed | Phase 1 | Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | January 1997 | December 2002 |
| NCT00006253 | Completed | N/A | Pain and Fatigue Study | March 2003 | October 2006 |
| NCT00034879 | Completed | Phase 3 | Iressa Expanded Access Program (EAP) | August 2000 | October 2003 |
| NCT00097903 | Completed | Phase 1 | Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer | May 2004 | May 2013 |
| NCT00099190 | Completed | Phase 1 | ARQ 501 in Combination With Docetaxel in Patients With Cancer | December 2004 | November 2006 |
| NCT00111774 | Completed | Phase 2 | Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma | March 2002 | |
| NCT00129051 | Completed | Phase 1 | Helical Tomotherapy as a Radiotherapy Technique for Treating Pelvic and Abdominal Metastases | August 2001 | November 2005 |
| NCT00152477 | Completed | Phase 2 | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | August 15, 2005 | June 25, 2009 |
| NCT00183742 | Completed | Phase 1 | Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) | December 2000 | May 2006 |
| NCT00191308 | Completed | Phase 2 | Molecular Profiling in Lung Cancer Patients | May 2005 | December 2010 |
| NCT00216372 | Completed | Phase 3 | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis | September 2003 | October 2008 |
| NCT00243347 | Completed | Phase 1 | The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer | December 2005 | July 2009 |
| NCT00301548 | Completed | Phase 2 | Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer | February 2000 | June 2005 |
| NCT01109524 | Completed | Phase 2 | Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer | July 2010 | September 2012 |
| NCT01215500 | Completed | Phase 1 | Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer | January 2005 | March 2018 |
| NCT01223209 | Completed | Phase 1 | A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma | August 2010 | January 2012 |
| NCT01253681 | Completed | Phase 1 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | November 2010 | January 2015 |
| NCT01299493 | Completed | N/A | Systems Intervention to Promote Colorectal Cancer (CRC) Screening | June 19, 2012 | September 21, 2017 |
| NCT01339975 | Completed | Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | June 6, 2011 | May 2019 | |
| NCT01398306 | Completed | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | July 2011 | April 2012 | |
| NCT01553825 | Completed | Assessment of Patient Experience During Treatment for Cancer | March 2012 | January 9, 2020 | |
| NCT01572493 | Completed | Phase 1 | Continuous Infusion of rhIL-15 for Adults With Advanced Cancer | April 4, 2012 | July 2, 2019 |
| NCT01614002 | Completed | A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer | May 2012 | March 2015 | |
| NCT01668108 | Completed | A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer | August 2012 | May 2018 | |
| NCT01752101 | Completed | Identification of a Plasma Proteomic Signature for Lung Cancer | October 2012 | December 2014 | |
| NCT01752114 | Completed | Early Diagnosis of Pulmonary Nodules | October 2012 | December 31, 2016 | |
| NCT01840280 | Completed | A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer | April 2013 | April 2018 | |
| NCT01916135 | Completed | Phase 1 | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative | July 2013 | April 23, 2020 |
| NCT01942200 | Completed | A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer | September 2013 | July 25, 2018 | |
| NCT02040467 | Completed | Registry for Proton Beam Radiation Therapy | December 18, 2013 | June 22, 2023 | |
| NCT02151149 | Completed | Phase 4 | Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly | June 9, 2014 | July 14, 2017 |
| NCT02507544 | Completed | Phase 1 | A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer | September 2015 | May 20, 2019 |
| NCT02539537 | Completed | Phase 3 | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | October 23, 2015 | September 25, 2023 |
| NCT02592577 | Completed | Phase 1 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | November 2015 | March 17, 2021 |
| NCT02703298 | Completed | Phase 1 | Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients | March 25, 2016 | May 3, 2018 |
| NCT02705105 | Completed | Phase 1/Phase 2 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | February 2016 | October 10, 2018 |
| NCT02737501 | Completed | Phase 3 | ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | May 26, 2016 | January 29, 2021 |
| NCT02834611 | Completed | Phase 1 | Ceramide NanoLiposome in Patients With Advanced Solid Tumors | March 15, 2017 | November 1, 2023 |
| NCT02840604 | Completed | What Benefit of a Full Analysis of Exome? Routine Care Study in Patients With Solid Tumors | May 15, 2016 | April 29, 2019 | |
| NCT02867007 | Completed | Phase 1 | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | August 2016 | December 15, 2019 |
| NCT02898116 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | May 10, 2017 | August 4, 2017 |
| NCT02965391 | Completed | Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients | November 2016 | November 2019 | |
| NCT03037385 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | March 17, 2017 | March 21, 2024 |
| NCT03320044 | Completed | Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing | October 18, 2017 | December 31, 2018 | |
| NCT03546166 | Completed | Phase 2 | Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma | July 26, 2018 | March 11, 2022 |
| NCT03562897 | Completed | Phase 2 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | October 25, 2018 | June 15, 2022 |
| NCT03611556 | Completed | Phase 1/Phase 2 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | June 21, 2018 | July 22, 2022 |
| NCT04008082 | Completed | A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma | May 14, 2019 | January 28, 2022 | |
| NCT04033991 | Completed | Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | September 27, 2019 | December 18, 2020 | |
| NCT04419207 | Completed | Detecting Lung Cancer Based on Exhaled Breath | March 1, 2019 | January 31, 2022 | |
| NCT04419623 | Completed | Phase 1 | A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer | July 9, 2020 | December 15, 2020 |
| NCT05375136 | Completed | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients | June 25, 2021 | November 7, 2023 | |
| NCT05593744 | Completed | Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma | August 17, 2020 | March 30, 2022 | |
| NCT05661370 | Completed | N/A | App Teaches Doctors to Diagnose Skin Cancer | November 15, 2021 | August 15, 2022 |
| NCT05848947 | Completed | Phase 4 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA | April 25, 2023 | July 5, 2023 |
| NCT00027326 | Enrolling by invitation | Collection of Blood and Urine From Patients Undergoing Radiation Therapy | December 2, 2001 | ||
| NCT02784158 | No longer available | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | |||
| NCT05744089 | Not yet recruiting | N/A | Home Management of Simple Hydromorphone PCA Pump Mode | February 2023 | February 2025 |
| NCT04962958 | Not yet recruiting | Phase 2 | Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | July 1, 2023 | August 2024 |
| NCT04807166 | Not yet recruiting | Phase 2 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | June 1, 2021 | December 1, 2024 |
| NCT06134193 | Not yet recruiting | Phase 2 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | November 2023 | June 2025 |
| NCT06112041 | Not yet recruiting | Phase 2 | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) | October 25, 2023 | October 30, 2026 |
| NCT06364046 | Not yet recruiting | N/A | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | April 1, 2024 | December 31, 2025 |
| NCT06445114 | Not yet recruiting | Phase 2 | Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer | July 2024 | July 2031 |
| NCT05115500 | Not yet recruiting | Phase 2 | ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) | November 1, 2021 | April 30, 2025 |
| NCT04985357 | Not yet recruiting | Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | June 2024 | May 2030 | |
| NCT05708950 | Recruiting | Phase 1/Phase 2 | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | March 3, 2023 | December 31, 2024 |
| NCT05752357 | Recruiting | The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer. | September 1, 2021 | August 31, 2024 | |
| NCT05860374 | Recruiting | Early Phase 1 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | March 2, 2023 | March 2, 2026 |
| NCT05910177 | Recruiting | Phase 2 | Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin | December 28, 2023 | August 31, 2026 |
| NCT05913661 | Recruiting | Phase 2 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | July 2023 | November 2024 |
| NCT05917106 | Recruiting | Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) | December 26, 2022 | June 2030 | |
| NCT05917158 | Recruiting | Phase 2 | A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma | November 23, 2022 | December 2028 |
| NCT05935748 | Recruiting | Phase 2 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | July 28, 2023 | September 2026 |
| NCT03331601 | Recruiting | Phase 2 | Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients | October 16, 2017 | December 2026 |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT05961111 | Recruiting | Early Phase 1 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | June 24, 2023 | June 2026 |
| NCT03549273 | Recruiting | Phase 2 | Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions | March 11, 2019 | January 15, 2025 |
| NCT06013111 | Recruiting | Phase 1 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors | October 23, 2023 | September 1, 2026 |
| NCT06022757 | Recruiting | Phase 1/Phase 2 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | September 20, 2023 | August 2028 |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT03708224 | Recruiting | Phase 2 | Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | March 8, 2019 | June 30, 2027 |
| NCT03778229 | Recruiting | Phase 2 | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | January 9, 2019 | May 28, 2025 |
| NCT06114940 | Recruiting | Phase 2 | Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | December 20, 2022 | December 31, 2025 |
| NCT04124198 | Recruiting | N/A | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | March 1, 2019 | January 2029 |
| NCT04401059 | Recruiting | Phase 4 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study | November 9, 2020 | March 30, 2026 |
| NCT06128343 | Recruiting | Anatomical-Clinical Base of Adenocarcinoma Pancreatic | November 16, 2023 | February 28, 2035 | |
| NCT04475705 | Recruiting | Phase 4 | Propofol vs Sevo for Paediatric Tumor Surgery | January 11, 2021 | July 2028 |
| NCT04787042 | Recruiting | Phase 1/Phase 2 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | August 6, 2021 | January 30, 2025 |
| NCT04897321 | Recruiting | Phase 1 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | July 6, 2022 | March 1, 2027 |
| NCT04931251 | Recruiting | N/A | Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings | November 11, 2021 | July 31, 2024 |
| NCT05065736 | Recruiting | Early Phase 1 | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer | March 6, 2023 | December 5, 2024 |
| NCT05094882 | Recruiting | Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010) | December 1, 2021 | June 30, 2024 | |
| NCT05129969 | Recruiting | Registry Platform Ovarian and Endometrial Cancer | November 25, 2021 | December 2027 | |
| NCT05180799 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | August 3, 2022 | June 30, 2025 |
| NCT05188729 | Recruiting | Phase 2 | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | February 1, 2022 | June 30, 2024 |
| NCT05225090 | Recruiting | N/A | Smartphone App for Cancer Medication Adherence | January 15, 2020 | April 15, 2024 |
| NCT05261399 | Recruiting | Phase 3 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | August 3, 2022 | December 17, 2026 |
| NCT05283226 | Recruiting | Phase 2 | Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | September 30, 2022 | January 2, 2025 |
| NCT06317311 | Recruiting | Phase 2 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | May 7, 2024 | August 31, 2027 |
| NCT05461430 | Recruiting | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) | July 15, 2022 | July 2026 | |
| NCT05463757 | Recruiting | Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study | November 1, 2021 | December 2024 | |
| NCT05494060 | Recruiting | Phase 2 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma | March 16, 2022 | February 2027 |
| NCT05520281 | Recruiting | N/A | Short-term Psychodynamic Psychotherapy in Serious Physical Illness | September 15, 2022 | June 30, 2025 |
| NCT05559879 | Recruiting | Phase 1/Phase 2 | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | August 20, 2023 | December 2025 |
| NCT02292641 | Recruiting | N/A | Beyond TME Origins | September 25, 2014 | December 2029 |
| NCT05592626 | Recruiting | Phase 1/Phase 2 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | January 4, 2023 | October 2026 |
| NCT06358222 | Recruiting | Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan | December 15, 2023 | December 31, 2027 | |
| NCT01125449 | Suspended | Phase 2 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | January 2011 | December 2014 |
| NCT01009593 | Terminated | Phase 3 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | January 2010 | July 2012 |
| NCT01097083 | Terminated | Phase 2 | Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma | April 2010 | October 2013 |
| NCT00804830 | Terminated | Phase 2 | Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer | April 2008 | December 2014 |
| NCT03549338 | Terminated | Phase 2 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | November 29, 2018 | March 9, 2019 |
| NCT00557596 | Terminated | Phase 1/Phase 2 | A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer | September 2007 | November 2009 |
| NCT00989092 | Terminated | Phase 2 | Darbepoetin Alfa and Anemia of Cancer | May 2002 | June 2004 |
| NCT01016054 | Terminated | Phase 1 | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | October 2009 | April 2010 |
| NCT02473094 | Terminated | Phase 2 | Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer | July 2015 | February 2016 |
| NCT05153408 | Terminated | Phase 1 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | January 13, 2022 | December 9, 2022 |
| NCT00672009 | Terminated | Phase 2 | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | April 2008 | August 2012 |
| NCT01479023 | Terminated | Phase 1 | Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors | April 2012 | March 2013 |
| NCT01214343 | Unknown status | Phase 3 | Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | October 2010 | September 2013 |
| NCT02526953 | Unknown status | Phase 3 | Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients | January 2016 | October 2022 |
| NCT02907606 | Unknown status | Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study | September 2016 | August 2020 | |
| NCT03288298 | Unknown status | Early Phase 1 | Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line | November 1, 2017 | April 1, 2019 |
| NCT04556071 | Unknown status | Phase 2 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | November 6, 2020 | October 1, 2022 |
| NCT01995942 | Unknown status | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | June 7, 2013 | February 2, 2022 | |
| NCT02005965 | Unknown status | Low Rectal Cancer Study (MERCURY II) | August 13, 2007 | March 11, 2021 | |
| NCT01361100 | Unknown status | N/A | Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract | December 2010 | June 2015 |
| NCT02696525 | Unknown status | Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients | December 2018 | December 2021 | |
| NCT03634826 | Unknown status | Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer). | August 15, 2018 | January 1, 2022 | |
| NCT03664843 | Unknown status | Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients | November 9, 2018 | September 1, 2020 | |
| NCT03699332 | Unknown status | Phase 1/Phase 2 | Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin | December 1, 2018 | September 2021 |
| NCT03301961 | Unknown status | Multiplex Analysis of Circulating Tumor DNA | April 11, 2019 | June 1, 2022 | |
| NCT04566952 | Unknown status | Phase 2 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | October 28, 2020 | October 1, 2023 |
| NCT00396617 | Unknown status | Phase 1 | Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy | December 2007 | March 2014 |
| NCT04697446 | Unknown status | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC | December 1, 2020 | October 31, 2021 | |
| NCT02303353 | Unknown status | Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy | October 2013 | September 2018 | |
| NCT00126269 | Unknown status | Phase 3 | Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary | May 2003 | |
| NCT02433574 | Unknown status | N/A | Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection | November 2015 | January 2019 |
| NCT01037049 | Unknown status | Phase 2 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | October 16, 2009 | December 8, 2019 |
| NCT02977364 | Unknown status | Phase 1 | A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours | November 2016 | November 2021 |
| NCT05023928 | Unknown status | Phase 1 | Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer | September 1, 2021 | September 1, 2023 |
| NCT02629978 | Unknown status | N/A | Radiofrequency Ablation of Malignant Pulmonary Nodules | October 2015 | October 2020 |
| NCT01149161 | Unknown status | Phase 2/Phase 3 | Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma | May 2009 | December 2020 |
| NCT00894569 | Unknown status | Phase 2 | Paclitaxel/Carboplatin With or Without Cetuximab in CUP | July 2009 | August 2011 |
| NCT02567734 | Unknown status | N/A | Clinical Trials of CT-guided Percutaneous Irreversible Electroporation（IRE）in the Treatment of Patients With Locally Advanced Tumors | October 2015 | January 2017 |
| NCT01556815 | Unknown status | Phase 2 | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma | May 2012 | May 2015 |
| NCT04124731 | Unknown status | Phase 2 | Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) | October 2019 | April 2022 |
| NCT05235607 | Unknown status | Phase 1 | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors | March 1, 2022 | December 2, 2023 |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT04429490 | Unknown status | N/A | Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma | June 12, 2020 | September 12, 2023 |
| NCT02833467 | Unknown status | Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA | January 2015 | June 2021 | |
| NCT03765775 | Unknown status | Phase 2 | Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | November 20, 2018 | December 31, 2021 |
| NCT01533324 | Unknown status | Phase 2 | S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC) | November 2011 | December 2016 |
| NCT03780283 | Unknown status | Phase 2 | Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | January 1, 2019 | January 1, 2022 |
| NCT03717038 | Withdrawn | Phase 3 | Sym004 Versus TAS-102 in Patients With mCRC | February 2019 | December 2025 |
| NCT01301612 | Withdrawn | Phase 2 | Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS) | January 2011 | |
| NCT00477425 | Withdrawn | A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab | June 2007 | June 2007 | |
| NCT02851693 | Withdrawn | N/A | Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection | June 1, 2016 | December 1, 2017 |
| NCT01467635 | Withdrawn | N/A | EBUS-TBNA Versus EBUS-TBNB | May 2014 | July 2016 |
| NCT01345084 | Withdrawn | Phase 3 | Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab | November 2013 | November 2017 |
| NCT04006691 | Withdrawn | Phase 3 | Efficacy and Safety of UGN-101 in Recurrent Patients | October 1, 2019 | March 31, 2020 |
| NCT03240393 | Withdrawn | Phase 2 | Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) | July 31, 2018 | October 26, 2021 |
- Disase is a (Disease Ontology)
- DOID:0050687
- Cross Reference ID (Disease Ontology)
- ICDO:8010/3
- Cross Reference ID (Disease Ontology)
- MESH:D002277
- Cross Reference ID (Disease Ontology)
- MESH:D009375
- Cross Reference ID (Disease Ontology)
- NCI:C2916
- Cross Reference ID (Disease Ontology)
- NCI:C3709
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:188083002
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:269513004
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:71298006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0007097
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0553707
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1368683
- Exact Synonym (Disease Ontology)
- epithelial cancer
- Exact Synonym (Disease Ontology)
- epithelioma
- Exact Synonym (Disease Ontology)
- malignant Epithelioma
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030731
- MeSH unique ID (MeSH (Medical Subject Headings))
- D002277